Welcome to our dedicated page for Maze Therapeutics SEC filings (Ticker: MAZE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Maze Therapeutics, Inc. (Nasdaq: MAZE) SEC filings page brings together the company’s public regulatory disclosures, offering a detailed view of how this clinical-stage biopharmaceutical company reports its activities to U.S. regulators. Maze focuses on small molecule precision medicines for kidney and metabolic diseases, and its filings provide context on both its scientific programs and its capital markets activity.
Maze’s filings include current reports on Form 8-K, which the company uses to announce material events such as quarterly financial results, leadership changes, and financing transactions. For example, Maze has filed 8-Ks to furnish press releases on second and third quarter financial results, to disclose an oversubscribed private placement of common stock and pre-funded warrants, and to document the appointments of a new chief financial officer and a new chairman of the board.
Investors can also review registration statements, such as the company’s Form S-1, which describes Maze’s business, risk factors, and the resale of shares issued in its 2025 private placement. The S-1 outlines Maze’s focus on human genetics, its Compass platform, and its lead programs MZE829 and MZE782, while also confirming its status as an emerging growth company and smaller reporting company.
Through Stock Titan, these filings are updated in near real time from the SEC’s EDGAR system, and AI-powered summaries help explain the key points of lengthy documents. Users can quickly understand what a particular 8-K, S-1, or other filing means for the company without reading every page. Where applicable, filings related to equity financings, registration rights, and governance changes are highlighted so investors can track dilution, board composition, and executive appointments.
For MAZE, monitoring SEC filings is especially relevant for understanding clinical development disclosures, financing capacity, and risk factors associated with its kidney and metabolic disease programs. This page serves as a central resource for reviewing those official documents alongside concise AI-generated explanations.
Jason V. Coloma, Chief Executive Officer and Director of Maze Therapeutics (MAZE), was granted 100,000 restricted stock units (RSUs) on 09/22/2025. Each RSU converts to one share of common stock upon settlement and the grant carries a $0 per-share price. The award vests in two equal installments: 50,000 RSUs on September 1, 2026 and 50,000 RSUs on September 1, 2027, contingent on continued service. The RSUs do not have an expiration date and will be cancelled if unvested prior to vesting.
Harold Bernstein, President, R&D & CMO of Maze Therapeutics, Inc. (MAZE), reported the grant of 40,000 restricted stock units (RSUs) on 09/22/2025. Each RSU represents a contingent right to one share of common stock upon settlement. The award vests in two equal installments: 20,000 RSUs vest on September 1, 2026 and 20,000 RSUs vest on September 1, 2027, subject to continued service. The RSUs have no exercise price and do not expire; they either vest or are cancelled prior to vesting. The reported ownership following the grant is 40,000 shares held directly. The Form 4 was signed by an attorney-in-fact on 09/24/2025.
Amy Bachrodt, SVP Finance of Maze Therapeutics (MAZE), was granted 22,000 restricted stock units on 09/22/2025. Each unit converts to one share of common stock upon settlement and the reporting person beneficially owns 22,000 shares after the reported transaction.
The award vests in two equal installments: 11,000 RSUs on September 1, 2026 and 11,000 RSUs on September 1, 2027, contingent on continued service. The RSUs have no expiration; they either vest or are cancelled before vesting. The Form 4 was executed by an attorney-in-fact on 09/24/2025.
Maze Therapeutics director Daniel K. Spiegelman received a stock option award on 09/22/2025. The Form 4 shows an option to buy 18,000 shares of Maze common stock at an exercise price of $23.67 per share. The option was reported as acquired on 09/22/2025 and is recorded as directly beneficially owned with 18,000 shares following the transaction. The option has an expiration/exercise date shown as 09/21/2035 and vests monthly in nine equal tranches (1/9 each) beginning with a first tranche vesting on October 1, 2025, subject to continued service. The filing was signed by an attorney-in-fact on 09/24/2025.
Catherine A. Sohn, a director of Maze Therapeutics, Inc. (MAZE), was granted a stock option on 09/22/2025 to purchase 18,000 shares of common stock at an exercise price of $23.67 per share. The option award vests monthly as to 1/9 of the total award, with the first tranche vesting on October 1, 2025, subject to continued service. The reported derivative shows 18,000 underlying shares and the reporting person is listed as owning 18,000 shares directly following the transaction. The form was signed by an attorney-in-fact on 09/24/2025.
Maze Therapeutics director Richard H. Scheller was granted a stock option for 18,000 shares on 09/22/2025 at an exercise price of $23.67 per share. The option is exercisable under an agreement that vests in nine equal monthly tranches (1/9 monthly) with the first tranche scheduled to vest on October 1, 2025, subject to continued service. The option has an expiration date shown as 09/21/2035. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 09/24/2025.
Maze Therapeutics director Jonathan E. Lim received a grant of stock options. The Form 4 reports an award of 18,000 stock options with an exercise price of $23.67, dated 09/22/2025. The options have an exercise price of $23.67 and underlying 18,000 shares of common stock, with an expiration date of 09/21/2035.
The filing states the option vests monthly as to 1/9 of the total award, beginning with a first tranche vesting on 10/01/2025, subject to continued service. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/24/2025.
Kathiresan Sekar, a director of Maze Therapeutics, Inc. (MAZE), reported the acquisition on 09/22/2025 of a stock option to buy 18,000 shares of common stock with an exercise price of $23.67. The option award vests in nine equal monthly tranches (1/9 each) beginning October 1, 2025, subject to continued service. The option shows an expiration or related date of 09/21/2035 and is reported as direct beneficial ownership. The Form 4 was signed by an attorney-in-fact, Courtney Phillips, on 09/24/2025.
Maze Therapeutics director Charles J. Homcy was granted a stock option to buy 18,000 shares of Maze Therapeutics common stock at an exercise price of $23.67 per share. The option is reported as a direct holding and covers 18,000 underlying shares with an exercise/expiration reference shown as 09/21/2035. The option vests monthly as to 1/9 of the award, with the first tranche vesting on October 1, 2025, subject to the holder’s continued service.
The grant increases the reporting person’s beneficial ownership by 18,000 shares on the reported transaction date of September 22, 2025. No cash exercise is indicated in the filing and the option is described as a right to buy common stock under standard vesting conditions tied to continued service.
Maze Therapeutics director Neil Exter was granted a stock option to buy 18,000 shares of Maze Therapeutics, Inc. (MAZE) at an exercise price of $23.67 per share. The option was granted on 09/22/2025, is exercisable beginning 09/21/2025, and expires 09/21/2035. The award vests in nine equal monthly tranches (1/9 each) with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service. The Form 4 was signed on 09/24/2025 by an attorney-in-fact.